<code id='07C8210A89'></code><style id='07C8210A89'></style>
    • <acronym id='07C8210A89'></acronym>
      <center id='07C8210A89'><center id='07C8210A89'><tfoot id='07C8210A89'></tfoot></center><abbr id='07C8210A89'><dir id='07C8210A89'><tfoot id='07C8210A89'></tfoot><noframes id='07C8210A89'>

    • <optgroup id='07C8210A89'><strike id='07C8210A89'><sup id='07C8210A89'></sup></strike><code id='07C8210A89'></code></optgroup>
        1. <b id='07C8210A89'><label id='07C8210A89'><select id='07C8210A89'><dt id='07C8210A89'><span id='07C8210A89'></span></dt></select></label></b><u id='07C8210A89'></u>
          <i id='07C8210A89'><strike id='07C8210A89'><tt id='07C8210A89'><pre id='07C8210A89'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:knowledge    Page View:7413
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In